A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
详细信息 查看全文
- 作者：Konstantinos Tryfonidisa ; 1 ; konstantinos.tryfonidis@eortc.be" class="auth_mail" title="E-mail the corresponding author ; Gul Basaranb ; 1 ; gabasaran@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Jan Bogaertsc ; jan.bogaerts@eortc.be" class="auth_mail" title="E-mail the corresponding author ; Marc Debledd ; M.Debled@bordeaux.unicancer.fr" class="auth_mail" title="E-mail the corresponding author ; Luc Dirixe ; Luc.dirix@telenet.be" class="auth_mail" title="E-mail the corresponding author ; Jean-Christophe Theryf ; jean-christophe.thery@chb.unicancer.fr" class="auth_mail" title="E-mail the corresponding author ; Vivianne C.G. Tjan-Heijneng ; vcg.tjan.heijnen@mumc.nl" class="auth_mail" title="E-mail the corresponding author ; Danielle Van den Weyngaerth ; Danielle.VandenWeyngaert@zna.be" class="auth_mail" title="E-mail the corresponding author ; Tanja Cuferi ; Tanja.Cufer@klinika-golnik.si" class="auth_mail" title="E-mail the corresponding author ; Martine Piccartj ; martine.piccart@bordet.be" class="auth_mail" title="E-mail the corresponding author ; David Cameronk ; D.Cameron@ed.ac.uk" class="auth_mail" title="E-mail the corresponding author ; on behalf of the EORTC-Breast Cancer Group
- 关键词：Anastrozole ; Gefitinib ; Metastatic breast cancer ; Endocrine resistance
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：53
- 期：Complete
- 页码：144-154
- 全文大小：741 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
Epidermal growth factor receptor inhibitors are believed to overcome/delay breast cancer endocrine resistance.
- class="label">•
Hormone receptor-positive metastatic women were randomized to anastrozole (A) and gefitinib (G) or placebo (P).
- class="label">•
1-Year progression-free survival rate was 35% for A/G and 32% for A/P.
- class="label">•
One-third of G arm patients stopped treatment due to intestinal and skin toxicities.
- class="label">•
Results do not support endocrine resistance delay by adding G to A.